Drugs / Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02379377 | Feb 2022 → May 2027 expected | adult hepatocellular carcinoma, cholangiocarcinoma, hepatobiliary benign neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02379377 ↗ |